5-lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents

被引：42

作者：

Jampilek, J

Dolezal, M

Opletalova, V

Hartl, J

机构：

[1] Zentiva AS, Prague 10237, Czech Republic

[2] Charles Univ Prague, Dept Pharmaceut Chem & Drug Control, Prague, Czech Republic

[3] Fac Pharm Hradec Kralove, Hradec Kralove 50005, Czech Republic

来源：

CURRENT MEDICINAL CHEMISTRY | 2006年 / 13卷 / 02期

关键词：

5-lipoxygenase; FLAP; LTA(4)-hydrolase; leukotrienes; antileukotrienic agents;

D O I：

10.2174/092986706775197935

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Leukotrienes play an important role in the inflammatory process accompanying allergic diseases of respiratory, gastrointestinal and dermatological systems. Leukotrienes are generated from arachidonic acid as a result of the 5-lipoxygenase action. This paper deals with 5-lipoxygenase action mechanism and the following biosynthesis of all leukotrienes. In this article, potential anti leukotrienic agents are classified according to their mechanism of action. The original antileukotrienic compounds of the Research Institute for Pharmacy and Biochemistry in Prague (VUFB), Czech Republic are presented in a separate chapter of the paper.

引用

页码：117 / 129

页数：13

共 103 条

[21]

COREY EJ, 1983, J AM CHEM SOC, V106, P1053

[22]

COUTTS SM, 1985, PROSTAGLANDINS LEUKO, P627

[23] LEUKOTRIENES ARE POTENT CONSTRICTORS OF HUMAN BRONCHI [J].

DAHLEN, SE ;

HEDQVIST, P ;

HAMMARSTROM, S ;

SAMUELSSON, B .

NATURE, 1980, 288 (5790) :484-486

[24] (E)-3-[[[[6-(2-CARBOXYETHENYL)-5-[[8-(4-METHOXYPHENYL)OCTYL]OXY]-2-PYRIDINYL]METHYL]THIO]METHYL]BENZOIC ACID AND RELATED-COMPOUNDS - HIGH-AFFINITY LEUKOTRIENE B-4 RECEPTOR ANTAGONISTS [J].

DAINES, RA ;

CHAMBERS, PA ;

EGGLESTON, DS ;

FOLEY, JJ ;

GRISWOLD, DE ;

HALTIWANGER, RC ;

JAKAS, DR ;

KINGSBURY, WD ;

MARTIN, LD ;

PENDRAK, I ;

SCHMIDT, DB ;

TZIMAS, MN ;

SARAU, HM .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (20) :3327-3336

[25] A DOUBLE-BLIND VEHICLE-CONTROLLED STUDY OF R-68-151 IN PSORIASIS - A TOPICAL 5-LIPOXYGENASE INHIBITOR [J].

DEGREEF, H ;

DOCKX, P ;

DEDONCKER, P ;

DEBEULE, K ;

CAUWENBERGH, G .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (05) :751-755

[26] PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ORAL DOSES OF MK-0591, A 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR [J].

DEPRE, M ;

FRIEDMAN, B ;

VANHECKEN, A ;

DELEPELEIRE, I ;

TANAKA, W ;

DALLOB, A ;

SHINGO, S ;

PORRAS, A ;

LIN, C ;

DESCHEPPER, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) :22-30

[27]

DEWHIRST FE, 1981, Patent No. 4244956

[28] THE PHARMACOLOGY OF ARACHIDONIC ACID-INDUCED RAT PMN LEUKOCYTE INFILTRATION [J].

DIMARTINO, MJ ;

WOLFF, CE ;

CAMPBELL, GK ;

HANNA, N .

AGENTS AND ACTIONS, 1989, 27 (3-4) :325-327

[29]

Djuric Stevan W., 1992, Drugs of the Future, V17, P819

[30] SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SC-53228, A LEUKOTRIENE B4 RECEPTOR ANTAGONIST WITH HIGH INTRINSIC POTENCY AND SELECTIVITY [J].

DJURIC, SW ;

DOCTER, SH ;

YU, SS ;

SPANGLER, D ;

TSAI, BS ;

ANGLIN, CP ;

GAGINELLA, TS ;

KACHUR, JF ;

KEITH, RH ;

MAZIASZ, TJ ;

VILLANIPRICE, D ;

RAO, TS ;

WALSH, RE ;

WIDOMSKI, DL ;

FRETLAND, DJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (06) :811-816

← 1 2 3 4 5 6 7 8 9 10 →